ABL Diagnostics Releases New Versions of DeepChek® and ViroScore® Software Applications
Woippy, France – ABL Diagnostics (FR001400AHX6 – ABLD), a company listed on Euronext that specializes in developing molecular biology assays and software for microbiology laboratories, has announced the release of new versions of its CE-IVD (In Vitro Diagnostics) DeepChek® and ViroScore® software applications (v3.30.115-ivdr). These web-based platforms, tailored to analyze Next Generation Sequencing (NGS) and Capillary Electrophoresis (SANGER) data from various sequencing systems, now include advanced functionalities to improve the management of sequencing data and integrate them into patient registries.
With a strong focus on innovation, ABL Diagnostics continues to develop its software applications to assist both routine and research settings in managing their sequencing data. The new versions of DeepChek® and ViroScore® now include optimized algorithms for the management of HIV-1 proviral DNA, as well as advanced expert systems for scrutinizing relevant genomic variations. These systems also allow for the analysis of longitudinal or cumulative samples from patients infected with the virus over time.
In addition, the software platforms are equipped with the latest clinical interpretation tools, providing relevant information such as drug resistance assessment, liver disease prognosis, vaccine escape determination, and virulence. These tools are consistently updated to adhere to the latest guidelines.
The release of the new interactive MicrobioChek software (v2.4.4) further expands ABL Diagnostics’ portfolio of applications, covering virology, bacteriology, and mycology. These fully integrated analysis software systems are coupled with a database that allows for reinterpretations of previously stored samples. They are also available worldwide within a matter of hours, either through local installations or a highly secure cloud service (HDS), in compliance with the highest international data protection regulations, such as the RGPD.
From raw sequence data to results, the DeepChek®, ViroScore®, and MicrobioChek® software platforms can be integrated with sequencing platforms, local Laboratory Information Systems (LIMS), and various Electronic Medical Record (EMR) systems, including Nadis, to provide a complete solution for optimizing disease management and targeting personalized medicine.
According to a report by 360 Research Reports, the global digital diagnostics market is anticipated to rise significantly between 2023 and 2030, with a projected market size of USD million by 2028, compared to USD million in 2021. ABL Diagnostics has been providing IT products and services to over 100 laboratories worldwide, helping them implement robust IT systems suitable for clinical genotyping in microbiology.
“Our company started as a software company in 2000. The experience and skills our entire team has developed over time is a real asset in offering the most advanced and innovative software systems for microbiology genotyping. We value the direct dialogue we have with our partners to constantly integrate functionalities that meet the expectations of end users.” said Mr. Matthieu Barralon, Head of Clinical at ABL SA.
About ABL Diagnostics
ABL Diagnostics S.A. (ABLD) is a leading international company that offers innovative and proprietary molecular biology assays and end-to-end solutions for molecular detection through Polymerase Chain Reaction (PCR) – UltraGene® and genotyping through DNA sequencing – DeepChek®. These products generate recurring revenues and cover one of the largest portfolios of microbiology applications, with a primary focus on HIV, SARS-CoV-2, Tuberculosis, and viral hepatitis B and C, among others. ABL Diagnostics also develops, manufactures, and markets kits for clinical specimen collection – MediaChek® and digital solutions like Nadis®, an Electronic Medical Record (EMR) system used in over 200 hospitals in France. ABL Diagnostics’ products are available worldwide through its own sales team and a network of exclusive distributors. The company’s clients include academic clinical pathology labs, private reference labs, and researchers. ABL Diagnostics is a public company listed on the regulated market of Euronext Paris (Euronext: ABLD – ISIN: FR001400AHX6).
For more information, please visit www.abldiagnostics.com.
Contacts
ABL Diagnostics
Ronan Boulme
General Manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
Forward-Looking Statements
This press release contains certain implicitly or explicitly forward-looking statements concerning ABL Diagnostics and its business. These forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that these forward-looking statements will be verified, as they are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.